Like with HR-positive patients, researchers found that patients with HR-negative or ER-low tumors lived longer on Enhertu than chemo after nearly three years.

NEW YORK – Akari Therapeutics on Wednesday said it hopes to raise $2.5 million by selling 3,125,000 American depositary shares (ADS) in a registered direct offering.

The funding includes an initial tranche of $7.5 million in equity and technical support, and the biotech and the foundation will form a joint steering committee.

In the histology-centric world of cancer medicine, further work is needed to increase genomic testing rates and educate ...

The firm amended the terms of a deal with Pfizer and submitted results from the BREAKWATER trial of Braftovi, Erbitux, and chemo against chemo alone.

The firm will use the funds to test its NaPi2b-targeted ADC in earlier lines of treatment and across tumor types, and another ADC in 5T4-expressing solid tumors.

The trial, performed at Radboud University Medical Center, will test TGW211, which involves a trigger designed to limit off-target effects of the radioactive material.

Two recent studies identified gene knockouts that may make CAR T-cell therapy more effective, but the next step is applying ...

The cell and gene therapy manufacturing company will provide services to advance early-stage translational R&D at Mass General Brigham.

The firm continues to seek needed funds to launch a Phase I/II trial of ELP-02 for this extremely rare form of ...

The company is studying the mRNA tumor-associated antigen vaccine as a monotherapy and in combination with Keytruda.